Second PCAC Peptides Meeting Expected by Early 2027
A second U.S. Food and Drug Administration Pharmacy Compounding Advisory Committee (PCAC) meeting on peptides is expected before the end of February 2027, with five more compounds slated for review. The gathering would follow the committee’s July 2026 session and continue a phased look at peptides proposed for possible inclusion on the Section 503A bulk drug substances list. As of this writing, the second meeting had been signaled by the FDA but not formally scheduled.
Which five peptides are expected next
Based on regulatory coverage of the FDA’s announcement, the five peptides expected at the follow-up meeting are:
- LL-37 (Cathelicidin)
- GHK-Cu
- Dihexa acetate
- Melanotan II
- PEG-MGF (Mechano Growth Factor, Pegylated)
As with the first group, these would be evaluated one compound at a time rather than as a single block.
How it fits the bigger picture
The July 23–24, 2026 PCAC meeting considered seven peptides — BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax and Epitalon. Taken together, the two meetings would address 12 of the 19 peptides that the FDA moved into “Category 2” of the 503A list in 2023, according to reporting by the Regulatory Affairs Professionals Society (RAPS) and analysis published on the FDA Law Blog. Both sources describe the review as deliberate and compound-by-compound.
What a committee review does — and doesn’t — mean
The PCAC is an advisory body, and its recommendations are non-binding. Any change to the 503A list still requires formal FDA notice-and-comment rulemaking, which can take considerable time. A meeting being expected is not the same as approval, market authorization, or any statement that a compound is safe or effective in people. It is one procedural step in a longer regulatory process, and the outcome of any future meeting is not predetermined.
Why the research community is watching
For laboratories and researchers, the significance here is regulatory clarity rather than product access. Compounds such as GHK-Cu and Melanotan II are frequently discussed research peptides, but whether and how they might eventually be compounded under 503A is a separate question from the laboratory handling, storage and characterization topics covered here. This post will be updated if and when the FDA confirms a date or agenda for the second meeting.
Related on VialHelp
- FDA advisory committee backs six of seven peptides for the 503A list
- GHK-Cu and Melanotan II in the compound library
- More VialHelp News
